The weight loss and diabetes drug market is booming with fierce competition and new developments. Eli Lilly and Novo Nordisk dominate, with Eli Lilly gaining market share and offering weekly injections. Demand is high, with the market expected to reach $100 billion by the end of the decade. New entrants are racing to capitalize on the growing market.

Eli Lilly leads in the injectable GLP-1 market, surpassing Novo Nordisk due to superior safety and efficacy. Real-world data shows Eli Lilly’s obesity injection Zepbound leads to more weight loss than Novo Nordisk’s Wegovy. Novo Nordisk’s stock has fallen 40% this year due to supply chain issues and compounded drugs affecting Wegovy’s market.

Novo Nordisk faces challenges from compounded versions of semaglutide, with Eli Lilly also dealing with similar issues. Both companies have ramped up manufacturing to address shortages. FDA declared an end to shortages of tirzepatide and semaglutide, restricting compounding of copycat drugs. Novo Nordisk’s experimental medicines face underwhelming data and pricing negotiations.

Limited insurance coverage for GLP-1s remains a barrier to patient access. Employers and health plans are hesitant due to high costs and concerns about side effects. Coverage for obesity drugs is increasing slightly, but questions remain about long-term efficacy and cost-effectiveness. Medicare plans to pilot coverage of weight loss drugs, potentially expanding access.

Novo Nordisk and Eli Lilly are racing to bring weight loss pills to market, potentially revolutionizing treatment access. Novo Nordisk’s oral semaglutide could be approved by the end of the year, offering a needle-free alternative. Eli Lilly’s oral pill, orforglipron, is seen as more easily absorbed and manufactured. Pills could capture a significant share of the weight loss drug market by 2030.

Competition in the weight loss drug space is intensifying, with new players entering the market. Experimental drugs from various companies are in development, aiming to offer innovative weight loss solutions. Some companies are exploring new approaches to weight loss treatment, such as targeting different gut hormones or preserving muscle mass. The future of the weight loss drug market remains uncertain as companies strive to meet patient needs.

Read more at CNBC: What’s next for the weight loss drug market: pills, rivals, insurance